Janux Therapeutics Q2 net loss narrows as expenses fall
Janux Therapeutics Q2 net loss narrows as expenses fall
Overview
Biopharmaceutical firm's Q2 collaboration revenue was $10.3 mln, with net loss narrowing yr/yr
Q2 operating expenses fell to $42.0 mln from $45.1 mln a year earlier
Company ended Q2 with $970.9 mln in cash and short-term investments
Outlook
Company expects initial clinical data for JANX011 in the second half of 2026
Janux plans clinical initiation of JANX013 in the second half of 2026
Company expects additional clinical data for JANX007 in the first half of 2027
Result Drivers
PIPELINE PROGRESS - Co said continued enrollment and advancement in multiple clinical trials, including JANX007, JANX014, and JANX011, shaped Q2 activity
LOWER R&D EXPENSES - Q2 research and development expenses declined yr/yr, contributing to a narrower net loss
Company press release: ID:nBw4xbz5Ja
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Collaboration Revenue |
| $10.27 mln |
|
Q2 Net Loss |
| $21.97 mln |
|
Q2 Loss Per Basic Share |
| $0.35 |
|
Q2 Operating Expenses |
| $41.96 mln |
|
Q2 Operating Income |
| -$31.69 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Janux Therapeutics, Inc. is $29.00, about 81.3% above its August 5 closing price of $16.00
Reuters Recommended Reads
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 6 - PepGen Q2 net loss narrows as expenses fall
Aug 5 - Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)